PhaseRx, Inc. (NASDAQ:PZRX) will post its Q3 2017 quarterly earnings results on Monday, November 6th. Analysts expect PhaseRx to post earnings of ($0.37) per share for the quarter.

PhaseRx (NASDAQ:PZRX) last issued its earnings results on Thursday, August 10th. The company reported ($0.30) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.09).

Shares of PhaseRx, Inc. (NASDAQ:PZRX) opened at $0.69 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 3.17 and a current ratio of 3.17. PhaseRx, Inc. has a 12-month low of $0.54 and a 12-month high of $3.30.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at

An institutional investor recently raised its position in PhaseRx stock. Vanguard Group Inc. grew its holdings in PhaseRx, Inc. (NASDAQ:PZRX) by 4.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 142,182 shares of the company’s stock after buying an additional 5,500 shares during the period. Vanguard Group Inc. owned 1.22% of PhaseRx worth $135,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 2.38% of the company’s stock.

Separately, Laidlaw cut shares of PhaseRx from a “buy” rating to a “neutral” rating in a research report on Friday, October 13th.

PhaseRx Company Profile

PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood.

Receive News & Ratings for PhaseRx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseRx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.